CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

30/09/2015 - 3 minutes

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo.

crispr_logo_grayAs Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed a lot. You can find out more on this review we wrote on how it will revolutionize therapeutics. Now even more so, according to Reuters, as co-discoverers Jennifer Doudna (UC Berkeley) and Emmanuel Charpentier (a French researcher now working in Berlin) have been short-listed to receive the next nobel prize next month.

Whilst CRISPR is a fantastic tool, it does involve a lot of patents which can complicate things. The main battle occurs between University of California, Berkeley and the Broad institute (MIT + Harvard) who fight over who invented the first CRISPR editing tools.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member